AR092330A1 - Composiciones, metodos de absorcion transmucosa y metodo de tratamiento - Google Patents
Composiciones, metodos de absorcion transmucosa y metodo de tratamientoInfo
- Publication number
- AR092330A1 AR092330A1 ARP130102101A ARP130102101A AR092330A1 AR 092330 A1 AR092330 A1 AR 092330A1 AR P130102101 A ARP130102101 A AR P130102101A AR P130102101 A ARP130102101 A AR P130102101A AR 092330 A1 AR092330 A1 AR 092330A1
- Authority
- AR
- Argentina
- Prior art keywords
- absorption
- transmucous
- compositions
- methods
- treatment method
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000010521 absorption reaction Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 abstract 1
- 229960000836 amitriptyline Drugs 0.000 abstract 1
- 239000002610 basifying agent Substances 0.000 abstract 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 abstract 1
- 229960003572 cyclobenzaprine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660593P | 2012-06-15 | 2012-06-15 | |
| US201261667774P | 2012-07-03 | 2012-07-03 | |
| US201261725402P | 2012-11-12 | 2012-11-12 | |
| US201361792900P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092330A1 true AR092330A1 (es) | 2015-04-15 |
Family
ID=49758769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102101A AR092330A1 (es) | 2012-06-15 | 2013-06-14 | Composiciones, metodos de absorcion transmucosa y metodo de tratamiento |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20140171515A1 (enExample) |
| EP (1) | EP2861223B1 (enExample) |
| JP (5) | JP6259452B2 (enExample) |
| CN (2) | CN111388430A (enExample) |
| AR (1) | AR092330A1 (enExample) |
| AU (2) | AU2013274003B2 (enExample) |
| BR (1) | BR112014031394B1 (enExample) |
| CA (2) | CA3118913C (enExample) |
| DK (1) | DK2861223T3 (enExample) |
| ES (1) | ES2929133T3 (enExample) |
| HR (1) | HRP20221325T1 (enExample) |
| HU (1) | HUE060175T2 (enExample) |
| IL (1) | IL236268B (enExample) |
| LT (1) | LT2861223T (enExample) |
| MX (2) | MX382516B (enExample) |
| MY (1) | MY194495A (enExample) |
| NZ (2) | NZ631144A (enExample) |
| PL (1) | PL2861223T3 (enExample) |
| PT (1) | PT2861223T (enExample) |
| RS (1) | RS63822B1 (enExample) |
| SG (2) | SG11201408318RA (enExample) |
| SI (1) | SI2861223T1 (enExample) |
| SM (1) | SMT202200436T1 (enExample) |
| TW (3) | TWI590820B (enExample) |
| WO (1) | WO2013188847A1 (enExample) |
| ZA (1) | ZA201500288B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011062614A1 (en) | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| NZ747040A (en) | 2013-03-15 | 2020-02-28 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| SG11201701995PA (en) | 2014-09-18 | 2017-04-27 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| JP6720301B2 (ja) * | 2015-07-15 | 2020-07-08 | テラネクス | 脳のヘミチャネルを遮断するためのアミトリプチリンの使用及びその効果をｉｎ ｖｉｖｏで増強する方法 |
| US12337063B2 (en) * | 2016-09-02 | 2025-06-24 | University Of Sharjah | Formulation for atropine sulfate rapidly-disintegrating sublingual tablets |
| CA3069699A1 (en) * | 2017-07-13 | 2019-01-17 | Tonix Pharmaceuticals Holding Corp. | Analogs of cyclobenzaprine and amitryptilene |
| CN107519142B (zh) * | 2017-08-24 | 2021-02-26 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下片及其制备方法 |
| CN107496355B (zh) * | 2017-08-24 | 2021-04-30 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下喷雾剂及其制备方法 |
| BR112020004035A2 (pt) * | 2017-12-08 | 2020-09-01 | F. Hoffmann-La Roche Ag | formulação farmacêutica |
| AU2018383098B2 (en) | 2017-12-11 | 2024-12-12 | Tonix Pharma Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
| CN108721240A (zh) * | 2018-06-08 | 2018-11-02 | 华益药业科技(安徽)有限公司 | 一种25mg阿米替林薄膜包衣片处方和工艺规程 |
| CA3109258A1 (en) | 2018-08-20 | 2020-02-27 | Tonix Pharma Holdings Limited | Methods of treating acute stress disorder and posttraumatic stress disorder |
| CA3156118A1 (en) * | 2019-09-30 | 2021-04-08 | Cadila Healthcare Limited | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CYCLOBENZAPRINE |
| CA3179754A1 (en) | 2020-04-08 | 2021-10-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for sexual dysfunction |
| US20240009146A1 (en) * | 2020-11-20 | 2024-01-11 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for alcohol use disorder |
| AU2021396509A1 (en) | 2020-12-07 | 2023-06-29 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for fibromyalgia |
| WO2022170107A2 (en) | 2021-02-04 | 2022-08-11 | Tonix Pharmaceuticals Holding Corp. | An improved method of assessing clinical response in the treatment of ptsd symptoms |
| EP4412602A1 (en) | 2021-10-06 | 2024-08-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients |
| WO2023250036A1 (en) | 2022-06-21 | 2023-12-28 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc) |
| JP2025067457A (ja) * | 2023-10-13 | 2025-04-24 | 株式会社島津製作所 | 液体クロマトグラフにおけるコストパフォーマンスの算出方法、プログラム、および、解析装置 |
| WO2025160302A1 (en) | 2024-01-25 | 2025-07-31 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for acute stress reaction or acute stress disorder |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| WO1999018937A1 (en) * | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
| AU3885799A (en) * | 1998-05-14 | 1999-11-29 | Alza Corporation | Antidepressant therapy |
| BR0013122A (pt) | 1999-08-13 | 2002-04-30 | Vela Pharmaceuticals Inc | Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina |
| DE60021266T2 (de) | 1999-08-13 | 2006-05-24 | L&L Technologies, Llc | Verwendungen von Zusammensetzungen zur Behandlung oder Vorbeugung von Schlafstörungen unter Verwendung von sehr niedrigen Dosen von Cyclobenzaprin |
| AU2001261744A1 (en) * | 2000-05-19 | 2001-12-03 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| WO2002094229A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of muscle relaxants through an inhalation route |
| WO2004071491A1 (en) * | 2003-02-04 | 2004-08-26 | Chrysalis Technologies Incorporated | Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
| US20090117054A1 (en) * | 2005-03-29 | 2009-05-07 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US20090148532A1 (en) * | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| JP2009079060A (ja) * | 2008-10-15 | 2009-04-16 | Novadel Pharma Inc | 極性または非極性の、バッカルスプレーまたはカプセル |
| US20100266682A1 (en) * | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| US20100247586A1 (en) * | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| WO2011062614A1 (en) * | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) * | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| ITMI20110558A1 (it) * | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
| NZ747040A (en) * | 2013-03-15 | 2020-02-28 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
-
2013
- 2013-06-14 EP EP13804115.7A patent/EP2861223B1/en active Active
- 2013-06-14 SM SM20220436T patent/SMT202200436T1/it unknown
- 2013-06-14 PT PT138041157T patent/PT2861223T/pt unknown
- 2013-06-14 JP JP2015517469A patent/JP6259452B2/ja active Active
- 2013-06-14 TW TW102121267A patent/TWI590820B/zh active
- 2013-06-14 HU HUE13804115A patent/HUE060175T2/hu unknown
- 2013-06-14 RS RS20221005A patent/RS63822B1/sr unknown
- 2013-06-14 MY MYPI2014703784A patent/MY194495A/en unknown
- 2013-06-14 NZ NZ631144A patent/NZ631144A/en unknown
- 2013-06-14 AU AU2013274003A patent/AU2013274003B2/en active Active
- 2013-06-14 SG SG11201408318RA patent/SG11201408318RA/en unknown
- 2013-06-14 HR HRP20221325TT patent/HRP20221325T1/hr unknown
- 2013-06-14 CN CN202010024102.2A patent/CN111388430A/zh active Pending
- 2013-06-14 MX MX2014015436A patent/MX382516B/es unknown
- 2013-06-14 BR BR112014031394-6A patent/BR112014031394B1/pt active IP Right Grant
- 2013-06-14 CA CA3118913A patent/CA3118913C/en active Active
- 2013-06-14 CA CA2876902A patent/CA2876902C/en active Active
- 2013-06-14 LT LTEPPCT/US2013/046023T patent/LT2861223T/lt unknown
- 2013-06-14 SG SG10201605407TA patent/SG10201605407TA/en unknown
- 2013-06-14 TW TW106117185A patent/TWI642429B/zh active
- 2013-06-14 US US13/918,692 patent/US20140171515A1/en not_active Abandoned
- 2013-06-14 ES ES13804115T patent/ES2929133T3/es active Active
- 2013-06-14 AR ARP130102101A patent/AR092330A1/es not_active Application Discontinuation
- 2013-06-14 TW TW107117266A patent/TWI683660B/zh active
- 2013-06-14 PL PL13804115.7T patent/PL2861223T3/pl unknown
- 2013-06-14 NZ NZ726488A patent/NZ726488A/en unknown
- 2013-06-14 WO PCT/US2013/046023 patent/WO2013188847A1/en not_active Ceased
- 2013-06-14 DK DK13804115.7T patent/DK2861223T3/da active
- 2013-06-14 MX MX2021005317A patent/MX2021005317A/es unknown
- 2013-06-14 CN CN201380039522.6A patent/CN104684550A/zh active Pending
- 2013-06-14 SI SI201332010T patent/SI2861223T1/sl unknown
-
2014
- 2014-12-15 IL IL236268A patent/IL236268B/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00288A patent/ZA201500288B/en unknown
-
2017
- 2017-10-02 JP JP2017192713A patent/JP2017222726A/ja not_active Withdrawn
-
2018
- 2018-10-04 AU AU2018241128A patent/AU2018241128B2/en active Active
-
2019
- 2019-05-14 JP JP2019091262A patent/JP2019123757A/ja not_active Withdrawn
-
2021
- 2021-06-16 JP JP2021100154A patent/JP2021138765A/ja not_active Withdrawn
-
2024
- 2024-02-02 JP JP2024014696A patent/JP2024032964A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
| BR112013018352A2 (pt) | composição de minociclina tópica e método | |
| HK1220980A1 (zh) | 用於治疗庞贝氏症的方法和组合物 | |
| CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
| EA033374B1 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| UA117466C2 (uk) | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 | |
| BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| AR089993A1 (es) | Macrociclos peptidomimeticos | |
| EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
| UY34676A (es) | ?cuchillo para tratamiento de madera, métodos para galvanizado y tratamiento de superficies de cuchillo para tratamiento de madera?. | |
| CL2015001772A1 (es) | Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma. | |
| MX2019009783A (es) | Metodo para fabricar una barra que comprende antitranspirante. | |
| CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
| MX382516B (es) | Composiciones y metodos para absorcion transmucosa. | |
| MX2016004741A (es) | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. | |
| BR112015006641A2 (pt) | composição farmacêutica de dose fixa, uso de uma composição farmacêutica de dose fixa, método para tratar sobrecarga crônica de ferro e processo para preparar uma composição farmacêutica de dose fixa | |
| MX365321B (es) | Métodos para el tratamiento de neutropenia mediante agonistas retinoides. | |
| BR112014031512A2 (pt) | composição cosmética e método para o tratamento cosmético. | |
| BR112014030553A2 (pt) | uso cosmético, como agente para prevenir e/ou tratar um defeito estético na pele e/ou seus apêndices, método relacionado, composto, e composição dermatológica | |
| PT2900251T (pt) | Novos extratos de cynara scolymus, coffea spp. e olea europaea para o tratamento da síndrome metabólica | |
| GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
| MX376175B (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| DK3003363T3 (da) | Immunogen sammensætning til anvendelse i terapi | |
| BR112015016391A2 (pt) | carboxamidas i baseadas em pirazolil como inibidoras do canal crac |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |